A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Abei, Masato ^a   Okumura, Toshiyuki ^b   Fukuda, Kuniaki ^a   Hashimoto, Takayuki ^b   Araki, Masahiro ^c   Ishige, Kazunori ^a   Hyodo, Ichinosuke ^a   Kanemoto, Ayae ^b   Numajiri, Haruko ^b   Mizumoto, Masashi ^b   Sakae, Takeji ^b   Sakurai, Hideyuki ^b   Zenkoh, Junko ^b   Ariungerel, Gerelchuluun ^b   Sogo, Yu ^d   Ito, Atsuo ^d   Ohno, Tadao ^e,f   Tsuboi, Koji ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^e WASEDA UNIVERSITY   (Japan)

^f Cell Medicine Inc   (Japan)

Author keywords

Hepatocellular carcinoma; Immunoadjuvant; Immunotherapy; Proton beam radiotherapy

Indexed keywords

BCG VACCINE; HYDROXYAPATITE; TUBERCULIN; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG FEVER; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; PROTON THERAPY; RADIATION DERMATITIS; RECURRENT CANCER; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VITAL SIGN; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYCOBACTERIUM BOVIS; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AGED; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DURAPATITE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; PROTON THERAPY; TUBERCULIN; VACCINATION;

EID: 84886544676     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-239     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
3. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2011, 365:1118-1127. 10.1056/NEJMra1001683, 21992124.
4. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009, 15:3210-3216. 10.3748/wjg.15.3210, 2710775, 19598295.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. 10.1002/hep.24199, 3084991, 21374666.
6. European Association for the study of Liver; European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: masnagement of hepatocellular carcinoma. Eur J Cancer 2012, 48:599-641. European Association for the study of Liver; European Organisation for Research and Treatment of Cancer.
7. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. Dig Dis 2011, 29:339-364. 10.1159/000327577, 21829027, HCC Expert Panel of Japan Society of Hepatology.
8. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier beams. J Clin Oncol 2007, 25:953-964. 10.1200/JCO.2006.09.7816, 17350944.
9. Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, Tsuji H, Tsujii H. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994, 106:1032-1041.
10. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005, 11:3799-3805. 10.1158/1078-0432.CCR-04-1350, 15897579.
11. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007, 37:676-691. 10.1111/j.1872-034X.2007.00119.x, 17617112.
12. Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, Shoda J, Sakurai H, Tsuboi K, Tokuuye K. Proton beam therapy for hepatocellular carcinoma: the university of Tsukuba experience. Cancer 2009, 115:5499-5506. 10.1002/cncr.24619, 19645024.
13. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ohkawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012, 82:e529-e535. 10.1016/j.ijrobp.2011.05.056, 22284041.
14. Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:805-812. 10.1016/j.ijrobp.2007.04.016, 17524568.
15. Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006, 107:591-598. 10.1002/cncr.22039, 16804931.
16. Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006, 182:713-720. 10.1007/s00066-006-1564-2, 3233367, 17149578.
17. Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tokita M, Tsuboi K, Tokuuye K. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 76:460-466. 10.1016/j.ijrobp.2009.02.030, 19427743.
18. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009, 185:782-788. 10.1007/s00066-009-2020-x, 20013087.
19. Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008, 71:462-467. 10.1016/j.ijrobp.2007.09.056, 18243571.
20. Nakayama H, Sugahara S, Fukuda K, Abei M, Shoda J, Sakurai H, Tsuboi K, Matsuzaki Y, Tokuuye K. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011, 80:992-995. 10.1016/j.ijrobp.2010.03.015, 21543162.
21. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 74:831-836. 10.1016/j.ijrobp.2008.10.073, 19304408.
22. Hashimoto T, Tokuuye K, Fukumitsu N, Igaki H, Hata M, Kagei K, Sugahara S, Ohara K, Matsuzaki Y, Akine Y. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:196-202. 10.1016/j.ijrobp.2005.11.043, 16563656.
23. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005, 23:1839-1846. 10.1200/JCO.2005.00.620, 15774777.
24. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy for hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004, 127:S189-S193. 10.1053/j.gastro.2004.09.033, 15508084.
25. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011, 117:3053-3059. 10.1002/cncr.25809, 21264826.
26. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y, Murakami M. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011, 117:4890-4904. 10.1002/cncr.26134, 21495022.
27. Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004, 10:1574-1579. 10.1158/1078-0432.CCR-03-0071, 15014006.
28. Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L, Huang J, Lu MD, Liang LJ, Leong KW, Ohno T. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 2002, 93:363-368. 10.1111/j.1349-7006.2002.tb01265.x, 11985784.
29. National Cancer Institute Common Terminology Criteria for Adverse Events v. 3.0 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, National Cancer Institute.
30. International Commission on Radiation Units and Measurements (ICRU) Recording and Reporting Proton-Beam Therapy. ICRU Report 78 2007, Bethesda: ICRU Publications, International Commission on Radiation Units and Measurements (ICRU).
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
32. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984, 2:187-193.
33. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 2011, 81:1039-1045. 10.1016/j.ijrobp.2010.07.015, 20888707.
34. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996, 334:1561-1567. 10.1056/NEJM199606133342402, 8628336.
35. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials. Int J Cancer 2009, 124:2982-2988. 10.1002/ijc.24311, 19296539.
36. Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Takano S, Enomoto T, Matsumura A, Ohno T. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007, 98:1226-1233. 10.1111/j.1349-7006.2007.00518.x, 17517052.
37. Muragaki Y, Maruyama T, Iseki H, Tanaka M, Shinohara C, Takakura K, Tsuboi K, Yamamoto T, Matsumura A, Matsutani M, Karasawa K, Shimada K, Yamaguchi N, Nakazato Y, Sato K, Uemae Y, Ohno T, Okada Y, Hori T. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma: clinical article. J Neurosurg 2011, 115:248-255. 10.3171/2011.4.JNS10377, 21568657.
38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
39. Kuang M, Liu SQ, Saijo K, Uchimura E, Huang L, Leong KW, Lu MD, Huang JF, Ohno T. Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: Induction of potent anti-residual tumour immunity. Int J Hyperthermia 2005, 21:247-257. 10.1080/02656730500052027, 16019851.
40. Zamai L, Rana R, Mazzotti G, Centurione L, Dipietro R, Vitale M. Lymphocyte binding to K562 cells: effect of target-cell irradiation and correlation with ICAM-1 and LFA-3 expression. Eur J Histochem 1994, 38:53-60.
41. Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994. 10.1158/0008-5472.CAN-04-1525, 15520206.
42. Ishikawa E, Tsuboi K, Saijo K, Takano S, Ohno T. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int J Radiat Oncol Biol Phys 2004, 59:1505-1512. 10.1016/j.ijrobp.2004.04.046, 15275738.
43. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059. 10.1038/nm1622, 17704786.
44. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010, 28:4324-4332. 10.1200/JCO.2010.28.9793, 2954133, 20697067.
45. LeGeros RZ, Ito A, Ishikawa K, Sakae T, LeGeros JP. Fundamentals of hydroxyapatite and related calcium phosphates. Advanced Biomaterials: Fundamentals, Processing, and Applications 2009, 19-52. Hoboken: Wiley, Bsasu B.
46. Ciocca DR, Frayssinet P, Cuello-Carrion FD. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and selfmantigens in cancer patients. Cell Stress Chaperones 2007, 12:33-43. 10.1379/CSC-218R.1, 1852891, 17441505.
47. Relyveld EH. Preparation and use of calcium phosphate adsorbed vaccines. Dev Biol Stand 1986, 65:131-136.
48. Jiang DP, Premachandra GS, Johnston C, Hem SL. Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine 2004, 23:693-698. 10.1016/j.vaccine.2004.06.029, 15542192.
49. Liu Y, Layrolle P, de Bruijn J, van Blitterswijk C, de Groot K. Biomimetic coprecipitaion of calcium phosphate and bovine serum albumin on titanium alloy. J Biomed Mater Res 2001, 57:327-335. 10.1002/1097-4636(20011205)57:3<327::AID-JBM1175>3.0.CO;2-J, 11523027.
50. Tsurushima H, Marushima A, Suzuki K, Oyane A, Sogo Y, Nakamura K, Matsumura A, Ito A. Enhanced bone formation using hydroxyapatite ceramic coated with fibroblast growth factor-2. Acta Biomater 2010, 6:2751-2759. 10.1016/j.actbio.2009.12.045, 20045091.
51. Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000, 25:246-250. 10.1007/s002610000025, 10823443.
52. Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transpl 2000, 6:67-72.